

Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

### Overview

#### **Useful For**

Monitoring patients undergoing diet therapy for mitochondrial or peroxisomal disorders (possibly inducing essential fatty acid deficiency in response to restricted fat intake) using plasma specimens

Monitoring treatment of essential fatty acid deficiency

Monitoring the response to provocative tests (fasting tests, loading tests)

### **Highlights**

This test is a comprehensive profile that provides information regarding mitochondrial and peroxisomal fatty acid metabolism and the patient's nutritional status.

#### **Method Name**

Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis

### **NY State Available**

Yes

### Specimen

### Specimen Type

Plasma

## Ordering Guidance

This test is **not** the recommended initial screening test for evaluating patients with possible peroxisomal disorders, single-enzyme defects of peroxisomal metabolism such as X-linked adrenoleukodystrophy, or peroxisomal biogenesis disorders (Zellweger syndrome spectrum). For these purposes, the preferred tests are either POXP / Fatty Acid Profile, Peroxisomal (C22-C26), Plasma or POX / Fatty Acid Profile, Peroxisomal (C22-C26), Serum.

### **Necessary Information**

- 1. Patient's age is required.
- 2. Include information regarding treatment, family history, and tentative diagnosis.

### Specimen Required

### **Patient Preparation:**

- 1. Fasting:
  - a. For nutritional assessment: 12 hours, required
  - b. For patients with a suspected fatty acid oxidation disorder, prolonged fasting is contraindicated. Collect as close to



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

the patient's next scheduled meal/feeding as possible.

2. Patient must not consume any alcohol for 24 hours before the specimen collection.

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

**Collection Container/Tube:** 

Preferred: Green top (sodium heparin)

Acceptable: Lavender top (EDTA) or green top (lithium heparin)

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot plasma into a plastic vial.

#### **Forms**

If not ordering electronically, complete, print, and send a <u>Biochemical Genetics Test Request</u> (T798) with the specimen.

### Specimen Minimum Volume

0.15 mL

### Reject Due To

Gross	OK
hemolysis	
Gross lipemia	Reject
Gross icterus	OK

### **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Plasma	Frozen (preferred)	92 days	
	Refrigerated	72 hours	

## **Clinical & Interpretive**

#### **Clinical Information**

Fatty Acid Deficiency/Excess:

Fats are important sources of energy for tissues and for the function and integrity of cellular membranes. Deficiencies are commonly caused by inadequate dietary intake of lipids due to an unbalanced diet, long-term parenteral nutrition, or by intestinal malabsorption. Linoleic acid, an omega-6 fatty acid, and alpha-linolenic acid, an omega-3 fatty acid, are considered essential fatty acids in that they cannot be made by the body and are essential components of the diet.

The major clinical manifestations associated with essential fatty acid deficiency (EFAD) include dermatitis, increased water permeability of the skin, increased susceptibility to infection, and impaired wound healing. Biochemical abnormalities may be detected before the onset of recognizable clinical manifestations. EFAD can be detected by diminished levels of the essential fatty acids, linoleic and alpha-linolenic acid, as well as by increases in the triene:tetraene ratio.



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

Excess dietary fatty acids have been linked to the onset of cardiovascular disease. Elevated levels of linoleic acid can contribute to overproduction of the proinflammatory 2-series local hormones. The Academy of Nutrition and Dietetics recommends that dietary fat for the healthy adult population should provide 20% to 35% of energy, with an increased consumption of n-3 polyunsaturated fatty acids and limited intake of saturated and trans fats.(1)

### Fatty Acid Oxidation Disorders:

Mitochondrial beta-oxidation is the main source of energy to skeletal and heart muscle during periods of fasting. When the body's supply of glucose is depleted, fatty acids are mobilized from adipose tissue and converted to ketone bodies through a series of steps providing an alternate source of energy. Deficient enzymes at any step in this pathway prevent the production of energy during periods of physiologic stress such as fasting or intercurrent illness.

The major clinical manifestations associated with fatty acid oxidation (FAO) disorders include hypoketotic hypoglycemia, liver disease and failure, skeletal myopathy, dilated/hypertrophic cardiomyopathy, and sudden unexpected death in early life. Signs and symptoms may vary greatly in severity, combination, and age of presentation. Life-threatening episodes of metabolic decompensation frequently occur after periods of inadequate calorie intake or intercurrent illness. When properly diagnosed, patients with FAO disorders respond favorably to fasting avoidance, diet therapy, and aggressive treatment of intercurrent illnesses, with significant reduction of morbidity and mortality.

Disease-specific characteristic patterns of metabolites from FAO disorders are detectable in blood, bile, urine, and cultured fibroblasts of living and many deceased individuals. Quantitative determination of C8-C18 fatty acids is an important element of the workup and differential diagnosis of candidate patients. Fatty acid profiling can detect quantitatively modest, but nevertheless significant, abnormalities even when patients are asymptomatic and under dietary treatment. Confirmatory testing for many of the FAO disorders is also available. For more information see FAO / Fatty Acid Oxidation Probe Assay, Fibroblast Culture and HFAOP / Fatty Acid Oxidation Gene Panel, Varies.

### Peroxisomal Disorders:

Peroxisomes are organelles present in all human cells except mature erythrocytes. They carry out essential metabolic functions including beta-oxidation of very long-chain fatty acids (VLCFA), alpha-oxidation of phytanic acid, and biosynthesis of plasmalogen and bile acids. Peroxisomal disorders include disorders of peroxisomal biogenesis with defective assembly of the entire organelle, and single peroxisomal enzyme/transporter defects where the organelle is intact but a specific function is disrupted. Peroxisomal beta-oxidation of VLCFA is impaired in all disorders of peroxisomal biogenesis and in selected single enzyme deficiencies, particularly X-linked adrenoleukodystrophy, resulting in elevated concentrations of VLCFA in serum or plasma. POXP / Fatty Acid Profile, Peroxisomal (C22-C26), Plasma or POX / Fatty Acid Profile, Peroxisomal (C22-C26), Serum is the preferred screening test for evaluating patients with possible peroxisomal disorders, single-enzyme defects of peroxisomal metabolism such as X-linked adrenoleukodystrophy, or peroxisomal biogenesis disorders (Zellweger syndrome spectrum). Confirmatory testing for X-linked adrenoleukodystrophy via molecular genetic analysis is available; see ABCD1 / X-Linked Adrenoleukodystrophy (XALD), ABCD1 Gene Sequencing with Deletion/Duplication, Varies.

### **Reference Values**

Octanoic Acid, C8:0 <1 year: 7-63 nmol/mL 1-17 years: 9-41 nmol/mL



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

> or =18 years: 8-47 nmol/mL

Decenoic Acid, C10:1 <1 year: 0.8-4.8 nmol/mL 1-17 years: 1.6-6.6 nmol/mL > or =18 years: 1.8-5.0 nmol/mL

Decanoic Acid, C10:0 <1 year: 2-62 nmol/mL 1-17 years: 3-25 nmol/mL > or =18 years: 2-18 nmol/mL

Lauroleic Acid, C12:1 <1 year: 0.6-4.8 nmol/mL 1-17 years: 1.3-5.8 nmol/mL > or =18 years: 1.4-6.6 nmol/mL

Lauric Acid, C12:0 <1 year: 6-190 nmol/mL 1-17 years: 5-80 nmol/mL > or =18 years: 6-90 nmol/mL

Tetradecadienoic Acid, C14:2 <1 year: 0.3-6.5 nmol/mL 1-17 years: 0.2-5.8 nmol/mL > or =18 years: 0.8-5.0 nmol/mL

Myristoleic Acid, C14:1 <1 year: 1-46 nmol/mL 1-17 years: 1-31 nmol/mL > or =18 years: 3-64 nmol/mL

Myristic Acid, C14:0 <1 year: 30-320 nmol/mL 1-17 years: 40-290 nmol/mL > or =18 years: 30-450 nmol/mL

Hexadecadienoic Acid, C16:2 <1 year: 4-27 nmol/mL 1-17 years: 3-29 nmol/mL > or =18 years: 10-48 nmol/mL

Hexadecenoic Acid, C16:1w9 <1 year: 21-69 nmol/mL



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

1-17 years: 24-82 nmol/mL > or =18 years: 25-105 nmol/mL

Palmitoleic Acid, C16:1w7 <1 year: 20-1,020 nmol/mL 1-17 years: 100-670 nmol/mL > or =18 years: 110-1,130 nmol/mL

Palmitic Acid, C16:0

<1 year: 720-3,120 nmol/mL 1-17 years: 960-3,460 nmol/mL > or =18 years: 1,480-3,730 nmol/mL

Gamma-Linolenic Acid, C18:3w6

<1 year: 6-110 nmol/mL 1-17 years: 9-130 nmol/mL > or =18 years: 16-150 nmol/mL

Alpha-Linolenic Acid, C18:3w3 <1 year: 10-190 nmol/mL 1-17 years: 20-120 nmol/mL > or =18 years: 50-130 nmol/mL

Linoleic Acid, C18:2w6

< or =31 days: 350-2,660 nmol/mL</pre>

32 days-11 months: 1,000-3,300 nmol/mL

1-17 years: 1,600-3,500 nmol/mL > or =18 years: 2,270-3,850 nmol/mL

Oleic Acid, C18:1w9

<1 year: 250-3,500 nmol/mL 1-17 years: 350-3,500 nmol/mL > or =18 years: 650-3,500 nmol/mL

Vaccenic Acid, C18:1w7 <1 year: 140-720 nmol/mL 1-17 years: 320-900 nmol/mL > or =18 years: 280-740 nmol/mL

Stearic Acid, C18:0

<1 year: 270-1,140 nmol/mL 1-17 years: 280-1,170 nmol/mL > or =18 years: 590-1,170 nmol/mL



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

EPA, C20:5w3

<1 year: 2-60 nmol/mL 1-17 years: 8-90 nmol/mL > or =18 years: 14-100 nmol/mL

Arachidonic Acid, C20:4w6 <1 year: 110-1,110 nmol/mL 1-17 years: 350-1,030 nmol/mL > or =18 years: 520-1,490 nmol/mL

Mead Acid, C20:3w9

< or =31 days: 8-60 nmol/mL
32 days-11 months: 3-24 nmol/mL
> or =1 year: 7-30 nmol/mL

Homo-Gamma-Linolenic Acid, C20:3w6

<1 year: 30-170 nmol/mL 1-17 years: 60-220 nmol/mL > or =18 years: 50-250 nmol/mL

Arachidic Acid, C20:0 <1 year: 30-120 nmol/mL 1-17 years: 30-90 nmol/mL > or =18 years: 50-90 nmol/mL

DHA, C22:6w3

<1 year: 10-220 nmol/mL 1-17 years: 30-160 nmol/mL > or =18 years: 30-250 nmol/mL

DPA, C22:5w6

<1 year: 3-70 nmol/mL 1-17 years: 10-50 nmol/mL > or =18 years: 10-70 nmol/mL

DPA, C22:5w3

<1 year: 6-110 nmol/mL 1-17 years: 30-270 nmol/mL > or =18 years: 20-210 nmol/mL

DTA, C22:4w6

<1 year: 2-50 nmol/mL 1-17 years: 10-40 nmol/mL > or =18 years: 10-80 nmol/mL



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

Docosenoic Acid, C22:1 <1 year: 2-20 nmol/mL > or =1 year: 4-13 nmol/mL

Docosanoic Acid, C22:0 0.0-96.3 nmol/mL

Nervonic Acid, C24:1 <1 year: 30-150 nmol/mL 1-17 years: 50-130 nmol/mL > or =18 years: 60-100 nmol/mL

Tetracosanoic Acid, C24:0 0.0-91.4 nmol/mL

Hexacosenoic Acid, C26:1 <1 year: 0.2-2.1 nmol/mL > or =1 year: 0.3-0.7 nmol/mL

Hexacosanoic Acid, C26:0 0.00-1.30 nmol/mL

Pristanic Acid, C15:0(CH3)4 < or =4 months: 0.00-0.60 nmol/mL 5-8 months: 0.00-0.84 nmol/mL 9-12 months: 0.00-0.77 nmol/mL 13-23 months: 0.00-1.47 nmol/mL > or =2 years: 0.00-2.98 nmol/mL

< or =4 months: 0.00-5.28 nmol/mL 5-8 months: 0.00-5.70 nmol/mL 9-12 months: 0.00-4.40 nmol/mL

Phytanic Acid, C16:0(CH3)4

13-23 months: 0.00-8.62 nmol/mL > or =2 years: 0.00-9.88 nmol/mL

Triene/Tetraene Ratio < or =31 days: 0.017-0.083 32 days-17 years: 0.013-0.050 > or =18 years: 0.010-0.038

Total Saturated Acid <1 year: 1.2-4.6 mmol/L



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

1-17 years: 1.4-4.9 mmol/L > or =18 years: 2.5-5.5 mmol/L

Total Monounsaturated Acid <1 year: 0.3-4.6 mmol/L 1-17 years: 0.5-4.4 mmol/L > or =18 years: 1.3-5.8 mmol/L

Total Polyunsaturated Acid <1 year: 1.1-4.9 mmol/L 1-17 years: 1.7-5.3 mmol/L > or =18 years: 3.2-5.8 mmol/L

Total w3

<1 year: 0.0-0.4 mmol/L 1-17 years: 0.1-0.5 mmol/L > or =18 years: 0.2-0.5 mmol/L

Total w6

<1 year: 0.9-4.4 mmol/L 1-17 years: 1.6-4.7 mmol/L > or =18 years: 3.0-5.4 mmol/L

**Total Fatty Acids** 

<1 year: 3.3-14.0 mmol/L 1-17 years: 4.4-14.3 mmol/L > or =18 years: 7.3-16.8 mmol/L

### Interpretation

An increased triene:tetraene ratio is consistent with essential fatty acid deficiency.

Fatty acid oxidation disorders are recognized on the basis of disease-specific patterns that are correlated to the results of other investigations in plasma (carnitine, acylcarnitines) and urine (organic acids, acylglycines).

Increased concentrations of very long-chain fatty acids (VLCFA) C24:0 and C26:0 are seen in peroxisomal disorders, X-linked adrenoleukodystrophy, adrenomyeloneuropathy, and Zellweger syndrome (cerebrohepatorenal syndrome).

Increased concentrations of phytanic acid (along with normal pristanic acid concentrations) are seen in Refsum disease (phytanase deficiency). Phytanic acid concentration also may be increased in other peroxisomal disorders and, when combined with the VLCFA, pristanic acid, and pipecolic acid, allows differential diagnosis of peroxisomal disorders.

#### Cautions

For nutritional assessment, a 12- to 14-hour fast is required; however, infants or persons suspected of having a fatty acid oxidation disorder should not fast before testing due to the possibility of acute metabolic decompensation. Instead,



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

collect the specimen after the longest fast possible, just before feeding. In the case of a patient on total parenteral nutrition (TPN), specimen can be collected as normal.

### Clinical Reference

- 1. Vannice G, Rasmussen H. Position of the Academy of Nutrition and Dietetics: Dietary fatty acids for healthy adults. J Acad Nutr Diet. 2014;114(1):136-153
- 2. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol. 2002;64:477-502
- 3. Jeppesen PB, Christensen MS, Hoy CE, Mortensen PB. Essential fatty acid deficiency in patients with severe fat malabsorption. Am J Clin Nutr. 1997;65(3):837-843
- 4. VerHoeven NM, Jakobs C. Human metabolism of phytanic acid and pristanic acid. Prog Lipid Res. 2001;40(6):453-466
- 5. Luszczki E, Boakye F, Zielinska M, et al. Vegan diet: nutritional components, implementation, and effects on adults' health. Front Nutr. 2023 9;10:1294497. doi:10.3389/fnut.2023.1294497
- Spector AA, Kim HY. Discovery of essential fatty acids. J. Lipid Res. 2015;56(1):11-21

### **Performance**

## **Method Description**

Quantitation of fatty acids of specific chain lengths is performed as follows: a 2-step, acid-base hydrolysis is followed by hexane extraction and derivatization with pentafluorobenzyl bromide. Separation and detection are accomplished by capillary gas chromatography electron-capture negative ion-mass spectrometry. Quantitation is based on analysis in the selected ion-monitoring mode by using 13 stable isotope-labeled internal standards. (Lagerstedt SA, Hinrichs DR, Batt SM, Magera MJ, Rinaldo P, McConnell JP. Quantitative determination of plasma C8-C26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders. Mol Genet Metab. 2001;73[1]:38-45; Gramlich L, Ireton-Jones C, Miles JM, Morrison M, Pontes-Arruda A. Essential fatty acid requirements and intravenous lipid emulsions. JPEN J Parenter Enteral Nutr. 2019;43[6]:697-707)

### **PDF Report**

No

### Day(s) Performed

Monday through Friday

### Report Available

3 to 5 days

### **Specimen Retention Time**

2 months

### **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus



Fatty Acid Profile, Comprehensive (C8-C26),
Plasma

### **Fees & Codes**

### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

### **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

### **CPT Code Information**

82725

### **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
PFAPC	Fatty Acid Profile, Comprehensive, P	43674-1

Result ID	Test Result Name	Result LOINC® Value
36595	Octanoic Acid, C8:0	35145-2
36596	Decenoic Acid, C10:1	35147-8
36597	Decanoic Acid, C10:0	35146-0
36598	Lauroleic Acid, C12:1	35151-0
36599	Lauric Acid, C12:0	35150-2
36600	Tetradecadienoic Acid, C14:2	35148-6
36601	Myristoleic Acid, C14:1	35158-5
36602	Myristic Acid, C14:0	35157-7
36603	Hexadecadienoic Acid, C16:2	35154-4
36604	Hexadecenoic Acid, C16:1w9	35155-1
36605	Palmitoleic Acid, C16:1w7	35162-7
36606	Palmitic Acid, C16:0	35161-9
36607	g-Linolenic Acid, C18:3w6	35163-5
36608	a-Linolenic Acid, C18:3w3	35164-3
36609	Linoleic Acid, C18:2w6	35165-0
36610	Oleic Acid, C18:1w9	35166-8
36611	Vaccenic Acid, C18:1w7	35167-6
36612	Stearic Acid, C18:0	35149-4
36613	EPA, C20:5w3	35173-4
36614	Arachidonic Acid, C20:4w6	35168-4
36615	Mead Acid, C20:3w9	35172-6
36616	h-g-Linolenic Acid, C20:3w6	35171-8



Fatty Acid Profile, Comprehensive (C8-C26), Plasma

36617	Arachidic Acid, C20:0	35169-2
36618	DHA, C22:6w3	35174-2
36619	DPA, C22:5w6	35181-7
36620	DPA, C22:5w3	35180-9
36621	DTA, C22:4w6	35182-5
36622	Docosenoic Acid, C22:1	35160-1
36623	Docosanoic Acid, C22:0	30194-5
36624	Nervonic Acid, C24:1w9	35170-0
36625	Tetracosanoic Acid, C24:0	30195-2
36626	Hexacosenoic Acid, C26:1	33036-5
36627	Hexacosanoic Acid, C26:0	30197-8
36628	Pristanic Acid, C15:0(CH3)4	22761-1
36629	Phytanic Acid, C16:0(CH3)4	22671-2
36630	Triene Tetraene Ratio	35411-8
36631	Total Saturated	35175-9
36632	Total Monounsaturated	35176-7
36633	Total Polyunsaturated	35177-5
36634	Total w3	35178-3
36635	Total w6	35179-1
36636	Total Fatty Acids	24461-6
36637	Interpretation (PFAPC)	59462-2